Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Vasomedical Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Cube who wrote (1310)	7/20/2000 1:50:50 PM
From: John Soileau	Read Replies (2) \| Respond to of 1605

A little anecdotal evidence that EECP and VASO have a good future. My mother had angioplasty and a stent, continued with some angina, and just got approved for EECP in Florida. She is on her 4th day of treatment, and feels a bit more energetic. I'm eager to see the difference after 35 treatments. She talks with other patients when she goes for treatment. One of them told her that after 10 treatments he is able to do things he hasn't done for years. Another patient told her climbing flights of stairs is no problem now, was nearly impossible before treatment. Her MD is very impressed with VASO so far. These are anecdotal reports but they are consistent with the study, and have me even more convinced that EECP will indeed romp in the next few years. One question that sticks around though is how does VASO keep making $$ after every center has bought all the machines they need? I'd like to see a pay per treatment business model, instead of just machine sales, to shore up the long term revenue picture. Regards John